Prescription Drug Price Relief Act of 2021
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 23, 2021)
Prescription Drug Price Relief Act of 2021
This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs.
Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.
Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population.
The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.
What just happenedOct 19, 2021
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Who’s behind it
- Introduced in HouseMar 23, 2021
- Oct 19, 2021Committee
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Administrative State, Regulatory Reform, and Antitrust Subcommittee - Mar 24, 2021Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 23, 2021IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Judiciary Committee - Mar 23, 2021IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Mar 23, 2021IntroReferralIntro-H
Introduced in House
- Mar 23, 2021IntroReferral1000
Introduced in House